Akebia Therapeutics, Inc.
AKBA
$3.19
$0.072.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 247.00K | 6.11M | -22.80M | -20.04M | -8.58M |
| Total Depreciation and Amortization | 316.00K | 314.00K | 13.54M | 9.37M | 9.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.68M | 9.71M | 8.03M | 11.63M | 2.75M |
| Change in Net Operating Assets | 5.10M | -29.73M | -3.23M | -7.66M | -13.64M |
| Cash from Operations | 22.35M | -13.59M | -4.47M | -6.70M | -10.07M |
| Capital Expenditure | -126.00K | -18.00K | -2.00K | -2.00K | -29.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 172.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -126.00K | 154.00K | -2.00K | -2.00K | -29.00K |
| Total Debt Issued | 0.00 | 10.00M | 0.00 | 0.00 | 8.00M |
| Total Debt Repaid | 0.00 | -462.00K | 1.00K | 0.00 | -374.00K |
| Issuance of Common Stock | 1.72M | 65.47M | 22.32M | 1.75M | 14.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -63.00K | 0.00 | -522.00K | 0.00 |
| Cash from Financing | 1.72M | 74.94M | 22.33M | 1.22M | 7.64M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.94M | 61.51M | 17.86M | -5.47M | -2.46M |